Biodexa implements ADR ratio change reducing outstanding shares

Biodexa Pharmaceuticals PLC (NASDAQ: BDRX) announced that its American Depositary Receipt ratio change became effective at the open of business on July 31, 2025. The ratio changed from one ADR representing 10,000 ordinary shares to one ADR representing 100,000 ordinary shares.

The change functions as a one-for-ten reverse ADR split for holders. JPMorgan Chase Bank, N.A., the depositary bank for the company's ADR program, automatically exchanged one new ADR for every ten previously-held ADRs, canceling the old ADRs and issuing new ones.

The company's total number of issued ordinary shares remains unchanged at 61,952,308,922. Following the ratio change, 619,523 ADRs are outstanding.

Biodexa is a clinical stage biopharmaceutical company developing products for diseases with unmet medical needs. The information is based on a company press release.

You May Also Be Interested In

• Sparton, Glen Eagle ink joint venture deal for Ontario silver mine
• Five Below (FIVE) call put ratio 1 call to 1.3 puts into quarter results
• NetApp (NTAP) call put ratio 2.3 calls to 1 put into quarter results